Effect of atorvastatin on blood sugar metabolism

Not Applicable

• Conditions: on-insulin-dependent diabetes mellitus.; Non-insulin-dependent diabetes mellitus

• Registration Number: IRCT201108177358N1
• Lead Sponsor: Arak university of medical sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

inclusion criteria: The patients with diabetes type 2 who had Hb A1C less than 9, triglyceride less than 250, low density lipoprotein ( LDL) between 70 to 160, high density lipoprotein (HDL) more than 35, total cholesterol less than 240 and are treated with oral hypoglycemic agents.
exclusion criteria: Evidence of diabetes complications such as retinopathy, nephropathy and Glomerular Filtration Rate(GFR) less than 60, cardiovascular involvement such as Congestive Heart Failure(CHF), Ischemic Heart Diseases(IHD), acute Myocardial Infarction (MI) during recent 1 year, history of epileptic disorders, history of significant active gastrointestinal diseases such as active peptic ulcer disease in recent 1 year, history of active significant hematologic , hepatic and musculoskeletal diseases , patients who treated with insulin, patients who affected to acute illness, allergic history to statins, history of alcohol and opium consumption, breast feeder mothers and pregnant patients, patients who have consumed statins during recent 6 months.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TNF-alpha. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;HsCRP. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;FBS. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Insulin. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Leptin. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Adiponektin. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.

Secondary Outcome Measures

Name	Time	Method
Side effects on liver enzymes. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.;Side effects on muscle enzymes. Timepoint: befor starting trial and 3 months later. Method of measurement: serologic methods.